Medication for the treatment of climacteric disorders :: Consumers survey results of for 1 quarter of 2019

Consumers survey results of for 1 quarter of 2019 in category

Gynecology, urology, nephrology / Medication for the treatment of climacteric disorders

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.		Ременс (Perrigo)	37.50%	5

2.	3	Клімадинон (Bionorica)	25.00%	3.33

3.	6	Овестин (Bayer)	20.00%	2.67

4.	3	Клімактоплан (DHU)	15.00%	2

4.	5	Лайфемин (Pro-Pharma)	15.00%	2

4.	8	Менопейс (Vitabiotics Ltd)	15.00%	2

7.	6	Клімаксан (Materia Medica – Ukraine)	12.50%	1.67

7.	2	Клімакт-хеель (Heel)	12.50%	1.67

7.	8	Клімапін (Red star)	12.50%	1.67

7.		Мулімен (Heel)	12.50%	1.67

11.	8	Трібестан (Sopharma)	10.00%	1.33

12.	4	Естрожель (Besins Healthcare)	7.50%	1

12.	7	Клеверол (Jadran)	7.50%	1

14.	6	Онагрис (Сперко Україна)	5.00%	0.67

14.	9	Циміциплант (Schwabe)	5.00%	0.67

16.	7	Клімакто-гран (Національна гомеопатична спілка)	2.50%	0.33

–.	10	Матрона (Талион-А)	0.00%	0

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2019, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.